Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study of Subcutaneous and Intravenous VELCADE in Patients With Previously Treated Multiple Myeloma

This study has been completed.
Sponsor:
Collaborator:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Information provided by (Responsible Party):
Millennium Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT00722566
First received: July 23, 2008
Last updated: October 6, 2011
Last verified: October 2011
Results First Received: August 30, 2011  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Multiple Myeloma
Interventions: Drug: VELCADE Administered by subcutaneous injection
Drug: VELCADE Administered by intravenous infusion

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
VELCADE Subcutaneous VELCADE 1.3 mg/m^2 administered by subcutaneous injection on Days 1, 4, 8, and 11 of a 3-week cycle for 8 cycles.
VELCADE Intravenous VELCADE 1.3 mg/m^2 administered by intravenous infusion on Days 1, 4, 8, and 11 of a 3-week cycle for 8 cycles.

Participant Flow:   Overall Study
    VELCADE Subcutaneous   VELCADE Intravenous
STARTED   148 [1]   74 
COMPLETED   81 [2]   39 [2] 
NOT COMPLETED   67   35 
[1] One patient randomized and not dosed
[2] Completed 8 cycles



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
VELCADE Subcutaneous VELCADE 1.3 mg/m^2 administered by subcutaneous injection on Days 1, 4, 8, and 11 of a 3-week cycle for 8 cycles.
VELCADE Intravenous VELCADE 1.3 mg/m^2 administered by intravenous infusion on Days 1, 4, 8, and 11 of a 3-week cycle for 8 cycles.
Total Total of all reporting groups

Baseline Measures
   VELCADE Subcutaneous   VELCADE Intravenous   Total 
Overall Participants Analyzed 
[Units: Participants]
 148   74   222 
Age 
[Units: Participants]
     
<=18 years   0   0   0 
Between 18 and 65 years   74   37   111 
>=65 years   74   37   111 
Age 
[Units: Years]
Mean (Standard Deviation)
 64.3  (8.96)   64.0  (12.11)   64.2  (10.09) 
Gender 
[Units: Participants]
     
Female   74   27   101 
Male   74   47   121 
Region of Enrollment 
[Units: Participants]
     
France   22   14   36 
Belgium   7   5   12 
Germany   2   4   6 
Netherlands   6   4   10 
United Kingdom   6   3   9 
Ukraine   51   17   68 
Russian Federation   26   9   35 
Poland   20   7   27 
Argentina   5   8   13 
India   3   3   6 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Number of Patients With Overall Response (Complete Response + Partial Response)   [ Time Frame: Over 4 cycles (prior to the addition of dexamethasone) ]
  Hide Outcome Measure 1

Measure Type Primary
Measure Title Number of Patients With Overall Response (Complete Response + Partial Response)
Measure Description

Disease response was measured according to European Group for Blood and Marrow Transplantation (EBMT) criteria with the addition of the response categories of nCR and VGPR.

Complete response requires disappearance of monoclonal protein from the blood and urine and <5% plasma cells in the bone marrow on at least 2 determinations for a minimum of 6 weeks.

Partial Response requires ≥50% reduction in serum m-protein for at least 2 determinations at least 6 weeks apart and if present, reduction in 24-hour urinary light chain excretion by either ≥90% or to <200 mg

Time Frame Over 4 cycles (prior to the addition of dexamethasone)  
Safety Issue No  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
The response-evaluable population was defined as subjects who received at least 1 dose of study drug and had measurable, secretory multiple myeloma, defined as a serum monoclonal IgG or IgM of ≥10 g/L or a serum monoclonal IgA or IgE ≥5 g/L, or a serum monoclonal IgD of ≥0.5g/L, or urine M-protein of ≥200 mg/24 hours, at study entry.

Reporting Groups
  Description
VELCADE Subcutaneuous VELCADE 1.3 mg/m^2 administered by subcutaneous injection on Days 1, 4, 8, and 11 of a 3-week cycle for 8 cycles.
VELCADE Intravenous VELCADE 1.3 mg/m^2 administered by intravenous injection on Days 1, 4, 8, and 11 of a 3-week cycle for 8 cycles.

Measured Values
   VELCADE Subcutaneuous   VELCADE Intravenous 
Participants Analyzed 
[Units: Participants]
 145   73 
Number of Patients With Overall Response (Complete Response + Partial Response) 
[Units: Participants]
 61   31 


Statistical Analysis 1 for Number of Patients With Overall Response (Complete Response + Partial Response)
Groups [1] All groups
Non-Inferiority/Equivalence Test [2] Yes
Method [3] Farrrington and Manning
P Value [4] 0.00201
ORR_SQ - 0.6 ORR_IV [5] 16.8
95% Confidence Interval 6.1 to 27.1
[1] Additional details about the analysis, such as null hypothesis and power calculation:
  In this trial, non-inferiority is defined as retaining 60% of the IV (active control) treatment effect as measured by ORR. The non-inferiority hypothesis can be stated as: H0: ORRSC – 0.60 ORRIV <0 vs. H1: ORRSC – 0.60 ORRIV ≥0 (non-inferiority).
[2] Details of power calculation, definition of non-inferiority margin, and other key parameters:
  Assuming ORRs are 35.5% for both SC and IV, one-sided alpha level of 0.025, and approximately 80% power, approximately 216 subjects (144 SC:72 IV) are needed to show non-inferiority of SC to IV VELCADE.
[3] Other relevant method information, such as adjustments or degrees of freedom:
  CONOR P. FARRINGTON AND GODFREY MANNING STATISTICS IN MEDICINE, VOL. 9, 1447-1454(1990).
[4] Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:
  No text entered.
[5] Other relevant estimation information:
  No text entered.



2.  Secondary:   Number of Patients With Complete Response   [ Time Frame: Over 4 cycles (prior to the addition of dexamethasone) ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information